Yahoo Finance Chief Financial Officer Matthew Ferguson Just Bought 79% More Shares In Aziyo Biologics, Inc. (NASDAQ:AZYO)
Even if it's not a huge purchase, we think it was good to see that Matthew Ferguson, the Chief Financial Officer of Aziyo Biologics, Inc. (NASDAQ:AZYO) recently shelled out US$95k to buy stock, at US$4.75 per share. Even though that isn't a massive buy, it did increase their holding by 79%, which is arguably a good sign.
Check out our latest analysis for Aziyo Biologics
The Last 12 Months Of Insider Transactions At Aziyo Biologics
Notably, that recent purchase by Matthew Ferguson is the biggest insider purchase of Aziyo Biologics shares that we've seen in the last year. That means that even when the share price was higher than US$3.59 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. In our view, the price an insider pays for shares is very important. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.
In the last twelve months Aziyo Biologics insiders were buying shares, but not selling. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Aziyo Biologics is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Does Aziyo Biologics Boast High Insider Ownership?
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. Based on our data, Aziyo Biologics insiders have about 2.9% of the stock, worth approximately US$1.7m. We prefer to see high levels of insider ownership.
What Might The Insider Transactions At Aziyo Biologics Tell Us?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. On this analysis the only slight negative we see is the fairly low (overall) insider ownership; their transactions suggest that they are quite positive on Aziyo Biologics stock. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. When we did our research, we found 6 warning signs for Aziyo Biologics (3 are a bit unpleasant!) that we believe deserve your full attention.
But note: Aziyo Biologics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
